Occupancy and mechanism in antibody-mediated neutralization of animal viruses

Journal of General Virology

Volumn 83, Issue 9, 2002, Pages 2091-2108

  Klasse, P J ^a   Sattentau, Q J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANTIBODY RESPONSE; ANTIBODY STRUCTURE; ANTIGEN BINDING; CONFORMATIONAL TRANSITION; HOST RESISTANCE; HUMAN; IMMUNOCHEMISTRY; IN VITRO STUDY; INFECTION RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; REVIEW; VIRION; VIRUS ADSORPTION; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION;

ANIMALIA;

EID: 0036711665     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-83-9-2091     Document Type: Review

References (132)

1. Observations on anti-phage sera. I. 'The percentage law'
2. Neutralization of influenza virus by low concentrations of hemagglutinin-specific polymeric immunoglobulin A inhibits viral fusion activity, but activation of the ribonucleoprotein is also inhibited
3. Varying temperature-dependence of post-attachment neutralization of human immunodeficiency virus type 1 by monoclonal antibodies to gp120: Identification of a very early fusion-independent event as a neutralization target
4. Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1
5. How many specific B cells are needed to protect against a virus?
6. The role of antibody concentration and avidity in antiviral protection
7. Potent broad cross-neutralizing sera inhibit attachment of primary HIV-1 isolates (groups m and o) to peripheral blood mononuclear cells
8. Structural studies on viral escape from antibody neutralization
9. Two antibodies that neutralize papillomavirus by different mechanisms show distinct binding patterns at 13 Å resolution
10. Hit-and-run neutralization of poliovirus
11. Lack of quantitative correlation between the neutralization of poliovirus and the antibody-mediated pI shift of the virions
12. Analysis of a highly immunodominant epitope in the human immunodeficiency virus type 1 transmembrane glycoprotein, gp4l, defined by a human monoclonal antibody
13. The immunological reactions of the filterable viruses
14. Vaccines and the induction of functional antibodies: Time to look beyond the molecules of natural infection?
15. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody
16. Antibody and virus: Binding and neutralization
17. A model for neutralization of viruses based on antibody coating of the virion surface
18. Influence of heavy chain constant regions on antigen binding and HIV-1 neutralization by a human monoclonal antibody
19. Core structure of gp41 from the HIV envelope glycoprotein
20. Antibody-mediated neutralization of human rhinovirus 14 explored by means of cryoelectron microscopy and X-ray crystallography of virus-Fab complexes
21. Inhibition of rhinovirus attachment by neutralizing monoclonal antibodies and their Fab fragments
22. A multi-hit model for the neutralization of animal viruses
23. Mechanisms of rabies virus neutralization by glycoprotein-specific monoclonal antibodies
24. Mechanisms of neutralization of animal viruses
25. A study of the basic aspects of neutralization. Two animal viruses: Western equine encephalitis virus and poliomyelitis virus
26. Two influenza A virus-specific Fabs neutralize by inhibiting virus attachment to target cells, while neutralization by their IgGs is complex and occurs simultaneously through fusion inhibition and attachment inhibition
27. Hemagglutinin 1-specific immunoglobulin G and Fab molecules mediate postattachment neutralization of influenza A virus by inhibition of an early fusion event
28. A haemagglutinin (HA1)-specific Fab neutralizes influenza A virus by inhibiting fusion activity
29. Bivalent attachment of antibody onto poliovirus leads to conformational alteration and neutralization
30. Shape and electrostatic complementarity at viral antigen-antibody complexes
31. The neutralization of viruses
32. Mechanisms of rabies virus neutralization
33. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex
34. The structure and function of a foot-and-mouth disease virus-oligosaccharide receptor complex
35. The role of the antibody response in influenza virus infection
36. Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus
37. Two monoclonal antibodies against La Crosse virus show host-dependent neutralizing activity
38. Affinity, complementarity, cooperativity, and specificity in antibody recognition
39. Dimensions of antigen recognition and levels of immunological specificity
40. Complementarity, specificity and the nature of epitopes and paratopes in multivalent interactions
41. Defining epitopes: It's not as easy as it seems
42. HIV: Early virus-cell interactions
43. Kinetic studies on the neutralization reaction between Japanese encephalitis virus and antiserum
44. Structure of neutralizing antibody bound bivalently to human rhinovirus 2
45. Structural studies on antibody interacting with viruses
46. Structure of the complex of a Fab fragment of a neutralizing antibody with foot-and-mouth disease virus: Positioning of a highly mobile antigenic loop
47. Structure of a neutralizing antibody bound monovalently to human rhinovirus 2
48. Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins
49. Neutralization of poliovirus by a monoclonal antibody: Kinetics and stoichiometry
50. The development of the phage-inactivating properties of serum during the course of specific immunization of an animal: Reversible and irreversible inactivation
51. Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1
52. Antiviral activity of antiserum specific for an influenza virus neuramimdase
53. Effects of specific monoclonal antibodies on La Crosse virus neutralization: Aggregation, inactivation by Fab fragments, and inhibition of attachment to baby hamster kidney cells
54. A hypothesis accounting for the effect of the host cell on neutralization-resistant virus
55. Role of adenovirus antigens in the induction of neutralizing antibody
56. Physico-chemical analysis of the humoral immune response to HIV-1: Quantification of antibodies, their binding to viral antigens and neutralization of viral infectivity
57. Quantitative model of antibody-and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1
58. Mechanisms of virus neutralization by antibodies
59. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 [HXB2-Env: Ala( → Thr)] decreases viral neutralization by monoclonal antibodies to the CD4-binding site
60. Mechanisms of enveloped virus entry into animal cells
61. Strain-specific neutralization of human cytomegalovirus isolates by human sera
62. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
63. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates
64. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus
65. Antibody neutralization of the extracellular enveloped form of vaccinia virus
66. HIV requires multiple gp120 molecules for CD4-mediated infection
67. Blocking of human immunodeficiency virus infection depends on cell density and viral stock age
68. Poliovirus neutralization by antibodies to internal epitopes of VP4 and VP1 results form reversible exposure of these sequences at physiological temperature
69. Human cytomegalovirus neutralizing antibody-resistant phenotype is associated with reduced expression of glycoprotein H
70. Effects of anti-gp120 monoclonal antibodies on CD4 receptor binding by the Env protein of human immunodeficiency virus type 1
71. Human immunodeficiency virus type 1 entry into T cells: More-rapid escape from an anti-V3 loop than from an antireceptor antibody
72. Mechanisms of human immunodeficiency virus type 1 (HIV-1) neutralization: Irreversible inactivation of infectivity by anti-HIV-1 antibody
73. 1 (b12) specific for the CD4-binding site of HIV-1 neutralizes by inhibiting the virus fusion entry process, but b12 Fab neutralizes by inhibiting a postfusion event
74. Neutralization of poliovirus: A hypothesis to explain the mechanism and the one-hit character of the neutralization reaction
75. Neutralization of animal viruses
76. Viral epitopes and monoclonal antibodies: Isolation of blocking antibodies that inhibit virus neutralization
77. Topographical analysis of viral epitopes using monoclonal antibodies: Mechanism of virus neutralization
78. Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies
79. 2-termini and V1/V2 and V3 loops, and sensitivity to neutralizing antibodies
80. Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans
81. HIV-1 neutralization: The consequences of viral adaptation to growth on transformed T cells
82. Dissociation of gp120 from HIV-1 virions induced by soluble CD4
83. Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development
84. Population dynamics of immune responses to persistent viruses
85. Polyclonal bovine sera but not virus-neutralizing monoclonal antibodies block bovine leukemia virus (BLV) gp51 binding to recombinant BLV receptor BLVRcp1
86. The antiviral activity of antibodies in vitro and in vivo
87. Structural and serological evidence for a novel mechanism of antigenic variation in foot-and-mouth disease virus
88. Role of CD4 endocytosis in human immunodeficiency virus infection
89. Reduction of HIV concentration during acute infection: Independence from a specific immune response
90. Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation
91. Studies on the mechanism of neutralization of influenza virus by antibody: Evidence that neutralizing antibody (anti-haemagglutinin) inactivates influenza virus in vivo by inhibiting virion transcriptase activity
92. Monoclonal antibodies which recognize the acidic configuration of the rabies glycoprotein at the surface of the virion can be neutralizing
93. Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization
94. Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins
95. An immunodominant N-terminal region of VP1 protein of poliovirus that is buried in the crystal structure can be exposed in solution
96. Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity
97. Antibodies to the trypsin cleavage peptide VP8 neutralize rotavirus by inhibiting binding of virions to target cells in culture
98. Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes
99. Crystal structure of a neutralizing human IgG against HIV-1: A template for vaccine design
100. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer
101. Antibody neutralization of HIV-1 and the potential for vaccine design
102. Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1
103. Stoichiometry of monoclonal antibody neutralization of T-cell line-adapted human immunodeficiency virus type 1
104. Receptor binding and membrane fusion in virus entry: The influenza hemagglutinin
105. Antibody interactions with rhinovirus: Lessons for mechanisms of neutralization and the role of immunity in viral evolution
106. Structure of human rhinovirus complexed with Fab fragments from a neutralizing antibody
107. Neutralizing antibody to human rhinovirus 14 penetrates the receptor-binding canyon
108. Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: Investigation of the mechanism of inhibition
109. Recent structural solutions for antibody neutralization of viruses
110. Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization
111. Antibody-mediated enhancement of viral disease
112. Quantitative relationships between an influenza virus and neutralizing antibody
113. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding
114. Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp4l amino acid change
115. Relationship between poliovirus neutralization and aggregation
116. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5
117. + target cells is a major mechanism of T cell line-adapted HIV-1 neutralization
118. HIV-1 attachment: Another look
119. Efficient neutralization of foot and mouth virus disease virus by monovalent antibody binding
120. Flexibility of the major antigenic loop of foot-and-mouth disease virus bound to a Fab fragment of neutralising antibody: Structure and neutralisation
121. Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6
122. Postabsorption neutralization of poliovirus
123. Effect of the cytoplasmic domain of the simian immunodeficiency virus envelope protein on incorporation of heterologous envelope proteins and sensitivity to neutralization
124. Preparation and properties of antibody directed specifically against the neuraminidase of influenza virus
125. Atomic structure of the ectodomain from HIV-1 gp41
126. Attachment of neutralizing antibodies stabilizes the capsid of poliovirus against uncoating
127. Neutralization of poliovirus by polyclonal antibodies requires binding of a single IgG molecule per virion
128. The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope
129. Neutralization of adenoviruses: Kinetics, stoichiometry, and mechanism
130. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5
131. Initial interaction of herpes simplex virus with cells is binding to heparan sulfate
132. Influenza A virus M2 protein: Monoclonal antibody restriction of virus growth and detection of M2 in virions